Praxis Precision Medicines Inc

NASDAQ:PRAXUnited States

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating insights from genetic epilepsies into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, is an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. Its product candidates include ulixacaltamide, PRAX-562, PRAX-628 and elsunersen.

Contact Information

Headquarters

99 High Street, 30th FloorBOSTON, MA, United States 02110

Phone

617-300-8460

Fax

302-655-5049

Executives

Independent Chairman of the Board

Dean Mitchell

President, Chief Executive Officer, Director

Marcio Souza

Chief Financial Officer

Timothy Kelly

General Counsel, Corporate Secretary

Alex Nemiroff

Independent Director

Jeffrey Chodakewitz